Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Doses First Patient in ASPENOVA Phase 3 for Ovarian Cancer

Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial (NCT07546500) evaluating azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). This randomized, controlled trial aims to confirm the clinical benefit of azenosertib monotherapy (400mg QD 5:2) against investigator's choice of standard-of-care chemotherapy in approximately 420 biomarker-selected patients. ASPENOVA is part of a dual-track regulatory strategy, designed to support full approval, while the ongoing DENALI Phase 2 trial is intended for accelerated approval with a topline readout expected by year-end 2026. Azenosertib is an investigational WEE1 inhibitor, and Cyclin E1 overexpression is a predictive biomarker for potential benefit.

• The ASPENOVA trial (NCT07546500) is a global, randomized, controlled Phase 3 study enrolling approximately 420 patients with Cyclin E1-positive platinum-resistant ovarian cancer. It compares azenosertib monotherapy (400mg QD 5:2) to investigator's choice of standard-of-care chemotherapy (paclitaxel, PLD, gemcitabine, or topotecan). The primary endpoint is progression-free survival (PFS), with key secondary endpoints including overall survival (OS) and overall response rate (ORR). This trial is designed to support full regulatory approval.
• Zentalis is pursuing a comprehensive dual-track regulatory strategy for azenosertib. The ASPENOVA Phase 3 trial serves as the confirmatory study for full approval, aligning with FDA requirements. Simultaneously, the company is advancing the registration-intended DENALI Phase 2 trial (NCT05128825), which is expected to provide topline readout by year-end 2026 and may support accelerated approval. This approach aims to expedite patient access to azenosertib.
• Azenosertib, a first-in-class WEE1 inhibitor, is being developed as a biomarker-driven treatment for Cyclin E1-positive platinum-resistant ovarian cancer, a population comprising approximately 50% of PROC patients with significant unmet medical need and poor outcomes. Cyclin E1 overexpression has been identified as a sensitive and specific predictive biomarker, guiding patient selection for azenosertib treatment and potentially offering a targeted, oral, non-chemo alternative to intravenous regimens.

The Persistent Challenges in Treating Cyclin E1-Positive PROC

Cyclin E1-positive platinum-resistant ovarian cancer represents a particularly challenging subset with significant unmet clinical needs. Despite decades of research, few predictive markers of chemotherapy resistance have been identified, and current treatment options remain severely limited for this patient population.

• Poor platinum sensitivity: Response rate to platinum retreatment is dramatically reduced in patients with CCNE1 gains (22%) compared to those without CCNE1 gains (83.5%, p = 0.041), demonstrating the inherent resistance mechanism

• Significantly worse survival outcomes: Patients with CCNE1 gains show markedly worse progression-free survival (3.7 vs 11.1 months, p = 0.008) and overall survival (7.1 vs 39.3 months, p = 0.007) compared to patients without CCNE1 gains

• Resistance to PARP inhibitor therapy: CCNE1-amplified tumors exhibit resistance to poly (ADP-ribose) polymerase inhibitors (PARPi), with patients in homologous recombination proficient (HRp) populations deriving minimal benefit from these agents

• Limited therapeutic options for HRp tumors: No clinical trials have compared PARPi and bevacizumab as maintenance therapy specifically in the HRp population, leaving treatment decisions without robust evidence

• Broad multi-drug resistance patterns: CCNE1/CCNE2 amplifications are associated with resistance across multiple therapeutic modalities including targeted therapies, immunotherapy, endocrine therapies, and chemo/radiotherapy

• Poor performance of novel targeted agents: In adavosertib monotherapy trials, CCNE1-amplified patients demonstrated 0% objective response rate and only 2 months progression-free survival, highlighting the challenges in developing effective targeted approaches

• High replication stress vulnerability remains unexploited: While HRp tumors with Cyclin E amplifications exhibit high replication stress that could theoretically be targeted, translation of this biological insight into effective therapies remains limited

Zentalis' Dual-Track Strategy: ASPENOVA and DENALI Trial Designs

Zentalis is advancing two pivotal trials targeting Cyclin E1-positive platinum-resistant ovarian cancer through distinct therapeutic approaches. The ASPENOVA trial evaluates azenosertib as monotherapy, while the DENALI trial investigates ZN-c3 in combination with chemotherapy, both specifically designed to address this challenging patient population with significant unmet medical need.

Azenosertib's WEE1 Inhibition in the Ovarian Cancer Landscape

Several WEE1 kinase inhibitors beyond azenosertib are being investigated for cancer treatment, sharing the same mechanism of action that targets the G2/M checkpoint preceding mitosis. These compounds are being evaluated as both monotherapy and in combination with DNA damaging agents, chemotherapy, and other targeted therapies across multiple cancer types.

Azenosertib's Phase 3: A Precision Play in Platinum-Resistant Ovarian Cancer

The launch of the Phase 3 ASPENOVA trial for azenosertib represents a significant strategic move in the challenging landscape of platinum-resistant ovarian cancer (PROC). This investigational WEE1 inhibitor is being evaluated as a monotherapy in patients whose tumors exhibit Cyclin E1 overexpression, a biomarker that has shown promise in predicting sensitivity to WEE1 inhibition. For patients with PROC, treatment options are often limited, and durable responses are scarce, underscoring a profound unmet medical need.

The rationale for targeting WEE1 is rooted in its critical role in regulating the G2/M cell cycle checkpoint. By inhibiting WEE1, cancer cells, particularly those with existing G1/S checkpoint deficiencies common in ovarian cancer due to TP53 mutations, are forced into mitosis prematurely, leading to increased replication stress and DNA damage. Prior clinical data with another WEE1 inhibitor, adavosertib, demonstrated an objective response rate of 36% in CCNE1-amplified epithelial ovarian cancer, providing a strong foundation for azenosertib's targeted approach.

This trial embodies a precision oncology strategy, aiming to identify and treat patients most likely to benefit, potentially leading to improved outcomes compared to unselected standard-of-care chemotherapy. The company's dual-track regulatory strategy, pursuing accelerated approval via the ongoing Phase 2 DENALI trial while simultaneously conducting the confirmatory Phase 3 ASPENOVA, signals confidence in azenosertib's potential and an ambition for rapid market entry.

However, several considerations warrant attention. WEE1 inhibitors have been associated with a distinct toxicity profile, notably myelosuppression, gastrointestinal issues, and fatigue. Managing these adverse events will be crucial for patient adherence and overall treatment success. Furthermore, research indicates that cancer cells can develop adaptive resistance to WEE1 inhibition through mechanisms involving the mTOR and PI3K/AKT pathways. This suggests that while initial responses may be promising, the durability of monotherapy efficacy will be a key determinant of its long-term clinical value. The robustness and prevalence of the Cyclin E1 biomarker in the broader PROC population will also be critical for defining the drug's ultimate market potential. A successful outcome for azenosertib could not only establish a new treatment paradigm for a specific subset of ovarian cancer but also further validate WEE1 inhibition as a targeted therapeutic strategy in oncology.